Recent ARDS News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:02:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 11:05:19 AM
- Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024 • GlobeNewswire Inc. • 12/15/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:00:31 PM
- Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/03/2023 08:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2023 10:15:10 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/14/2023 01:47:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/25/2023 08:05:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/04/2023 08:05:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/04/2023 08:05:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/03/2023 08:15:38 PM
- Aridis Pharmaceuticals Announces $2 Million Offering • GlobeNewswire Inc. • 08/02/2023 12:17:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2023 04:15:14 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/21/2023 10:49:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/20/2023 09:18:38 PM
- Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301 • GlobeNewswire Inc. • 07/17/2023 08:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/17/2023 07:01:05 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/17/2023 11:36:32 AM
- Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation • GlobeNewswire Inc. • 07/12/2023 12:00:00 PM
- Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) • GlobeNewswire Inc. • 06/20/2023 12:00:00 PM
- Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 06/08/2023 08:05:00 PM
- Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design • GlobeNewswire Inc. • 05/31/2023 12:00:00 PM
- Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q • GlobeNewswire Inc. • 05/25/2023 08:05:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM